<DOC>
	<DOCNO>NCT02836782</DOCNO>
	<brief_summary>New marker viral activity investigation . Aim study investigate efficacy new antiretroviral drug monitor HIV-DNA dynamic HIV-positive population . In HIV/HCV coinfected population , study HIV reservoir dynamic analysis prevalence HCV resistance-associated mutation help clinician improve management coinfected patient .</brief_summary>
	<brief_title>HIV-DNA Dynamics HIV Monoinfected HIV/HCV Coinfected Patients</brief_title>
	<detailed_description>New marker viral activity investigation . Besides HIV-RNA CD4 cell count , HIV-DNA emerge marker viral reservoir , seem associate risk HIV-related disease , especially HCV coinfected patient . New antiretroviral drug , particularly integrase inhibitor , expect decrease residual viremia , consequently , viral reservoir . Monitoring HIV-DNA dynamic antiretroviral treatment could lead well management HIV infect population . Also , role HCV influence HIV natural history require careful monitoring . In particular , broad use direct act antiretroviral , analysis prevalence HCV resistance associate mutation important manage patient treatment failure .</detailed_description>
	<criteria>Persons â‰¥ 18 yearsold ; Signing inform consent study participation data treatment ; HIVpositive patient , begin new antiretroviral treatment patient clinically relevant event ; HCVpositive patient begin antiviral treatment DAA . Patient 's deny Clinical contraindication blood sample withdrawal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HIV/HCV</keyword>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>HIV-DNA</keyword>
	<keyword>Direct act antiviral</keyword>
</DOC>